Details of the Drug

General Information of Drug (ID: DM9YSNQ)

Drug Name
Amfepramone
Synonyms
Diethylpropion; DIETHYLPROPION; Diethylpropione; Amfepramon; Tepanil; Anorex; Nopropiophenone; Frekentine; Amphepramon; Amfepramonum; Amphepramone; Adiposon; Tylinal; Magrene; Dobesin; Neobes; Danylen; alpha-Benzoyltriethylamine; Anfepramona; Cegramine; Obesitex; Silutin; Regenon; Prefamone; Derfon; alpha-Diethylaminopropiophenone; 90-84-6; Diethylcathinone; Amfepramonum [INN-Latin]; Anfepramona [INN-Spanish]; Amfepramone [INN]; Parabolin; Modulor; Keramik; Keramin; Anfamon; 2-(Diethylamino)propiophenone; 1-Phenyl-2-diethylamino-1-propanone; Adiposon; Danylen;Derfon; Phepranon; Reginon; Amfepramone HCL; Amfepramone hydrochloride; Amphepramonum hydrochloride; Diethylpropion HCL; Diethylpropione hydrochloride; Tenuate hydrochloride; UR 1423; Alpha-Benzoyltriethylamine; Alpha-Diethylaminopropiophenone; Amfepramone (INN); Diethylpropion (BAN); Fenyl-(1-diethylaminoethyl)keton; Fenyl-(1-diethylaminoethyl)keton [Czech]; (+-)-diethylpropion; 2-(Diethylamino)-1-phenyl-1-propanone; 2-(diethylamino)-1-phenylpropan-1-one; 2-Diethylaminopropiophenone
Indication
Disease Entry ICD 11 Status REF
Migraine 8A80 Approved [1], [2]
Obesity 5B81 Approved [3]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 205.3
Topological Polar Surface Area (xlogp) 2.8
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 4 - 6 hours [4]
Chemical Identifiers
Formula
C13H19NO
IUPAC Name
2-(diethylamino)-1-phenylpropan-1-one
Canonical SMILES
CCN(CC)C(C)C(=O)C1=CC=CC=C1
InChI
InChI=1S/C13H19NO/c1-4-14(5-2)11(3)13(15)12-9-7-6-8-10-12/h6-11H,4-5H2,1-3H3
InChIKey
XXEPPPIWZFICOJ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
7029
ChEBI ID
CHEBI:4530
CAS Number
90-84-6
DrugBank ID
DB00937
TTD ID
D0B7OD
VARIDT ID
DR01090
ACDINA ID
D00196

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [3], [5]
Serotonin transporter (SERT) TT3ROYC SC6A4_HUMAN Inhibitor [3], [5]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Migraine
ICD Disease Classification 8A80
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Serotonin transporter (SERT) DTT SLC6A4 8.76E-01 7.18E-05 6.19E-04
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Amfepramone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Increased risk of hyperpyrexia by the combination of Amfepramone and Methylene blue. Acquired methaemoglobinaemia [3A93] [17]
Droxidopa DM5YF4M Moderate Additive hypertensive effects by the combination of Amfepramone and Droxidopa. Autonomic nervous system disorder [8D87] [18]
Selegiline DM6034S Major Increased risk of hyperpyrexia by the combination of Amfepramone and Selegiline. Depression [6A70-6A7Z] [17]
Isocarboxazid DMAF1NB Major Increased risk of hyperpyrexia by the combination of Amfepramone and Isocarboxazid. Depression [6A70-6A7Z] [17]
Esketamine DMVU687 Major Additive hypertensive effects by the combination of Amfepramone and Esketamine. Depression [6A70-6A7Z] [19]
Procarbazine DMIK367 Major Increased risk of hyperpyrexia by the combination of Amfepramone and Procarbazine. Hodgkin lymphoma [2B30] [17]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Amfepramone and Polyethylene glycol. Irritable bowel syndrome [DD91] [20]
Ozanimod DMT6AM2 Major Additive hypertensive effects by the combination of Amfepramone and Ozanimod. Multiple sclerosis [8A40] [17]
Promethazine DM6I5GR Moderate Antagonize the effect of Amfepramone when combined with Promethazine. Nausea/vomiting [MD90] [21]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Amfepramone and Bupropion. Nicotine use disorder [6C4A] [22]
Safinamide DM0YWJC Moderate Decreased metabolism of Amfepramone caused by Safinamide mediated inhibition of non-CYP450 enzyme. Parkinsonism [8A00] [23]
Rasagiline DM3WKQ4 Moderate Additive hypertensive effects by the combination of Amfepramone and Rasagiline. Parkinsonism [8A00] [17]
Levomepromazine DMIKFEL Moderate Antagonize the effect of Amfepramone when combined with Levomepromazine. Psychotic disorder [6A20-6A25] [21]
Trimeprazine DMEMV9D Moderate Antagonize the effect of Amfepramone when combined with Trimeprazine. Vasomotor/allergic rhinitis [CA08] [24]
⏷ Show the Full List of 14 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Crospovidone E00626 Not Available Disintegrant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid E00029 875 Acidulant; Complexing agent; Flavoring agent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Zinc stearate E00209 11178 lubricant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 11 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Diethylpropion 75 mg tablet 75 mg 24 HR Extended Release Oral Tablet Oral
Diethylpropion 25 mg tablet 25 mg Oral Tablet Oral
Diethylpropion Hydrochloride 25mg tablet 25mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7161).
2 Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci. 2008 Apr;29(4):208-17.
3 Pharmacotherapy for obesity. Drugs. 2005;65(10):1391-418.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Phentermine and anaesthesia. Anaesth Intensive Care. 2005 Aug;33(4):525-7.
6 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
7 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
8 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
9 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
10 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
11 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
12 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
13 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
14 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
15 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
16 Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
17 Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6. [PMID: 1116424]
18 Product Information. Northera (droxidopa). Chelsea Therapeutics Inc, Charlotte, NC.
19 Cerner Multum, Inc. "Australian Product Information.".
20 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
21 Achor MB, Extein I "Diet aids, mania, and affective illness" Am J Psychiatry 138 (1981): 392. [PMID: 7468847]
22 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
23 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
24 Lake CR "Manic psychosis after coffee and phenylpropanolamine." Biol Psychiatry 30 (1991): 401-4. [PMID: 1912131]